Author details

Full Name

Jeffrey J Kovacs

Affiliation

ORCID

Career Start Year

2002

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36689560	Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.	Clin Cancer Res	2023
36627494	Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.	Nature	2023
35944232	Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set.	JCO Clin Cancer Inform	2022
35705814	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.	Nature	2022
34330913	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.	Nat Commun	2021
32787110	Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.	Journal of Medicinal Chemistry	2020
32928921	Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.	Cancer Res	2020
33118821	Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.	J Med Chem	2020
30986992	Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer.	Cancers (Basel)	2019
31719531	ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer.	Nat Commun	2019
30586762	Vascular Endothelial Growth Factor Receptor 3 Regulates Endothelial Function Through Î²-Arrestin 1.	Circulation	2019
24736311	Targeted disruption of Î²-arrestin 2-mediated signaling pathways by aptamer chimeras leads to inhibition of leukemic cell growth.	PLoS ONE	2014
24255721	Î²-Arrestin regulation of myosin light chain phosphorylation promotes AT1aR-mediated cell contraction and migration.	PLoS ONE	2013
22773819	Î²-Arrestin2 mediates the initiation and progression of myeloid leukemia.	Proceedings of the National Academy of Sciences of the United States of America	2012
21857681	A stress response pathway regulates DNA damage through Î²2-adrenoreceptors and Î²-arrestin-1.	Nature	2011
21411739	Î²-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix.	Science Translational Medicine	2011
20686112	Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR).	Proc Natl Acad Sci U S A	2010
19853559	Arrestin development: emerging roles for beta-arrestins in developmental signaling pathways.	Developmental Cell	2009
19349687	beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice.	J Clin Invest	2009
18534983	Beta-arrestin scaffolding of phosphatidylinositol 4-phosphate 5-kinase Ialpha promotes agonist-stimulated sequestration of the beta2-adrenergic receptor.	Journal of Biological Chemistry	2008
17512543	Solution structure of the Ubp-M BUZ domain, a highly specific protein module that recognizes the C-terminal tail of free ubiquitin.	Journal of Molecular Biology	2007
16604172	Chaperoning steroid hormone signaling via reversible acetylation.	Nuclear receptor signaling	2005
16087666	Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone.	Journal of Biological Chemistry	2005
15916966	HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.	Molecular Cell	2005
15171253	The HDAC complex and cytoskeleton.	Novartis Foundation Symposium	2004
14675537	The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress.	Cell	2003
12426395	MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation.	EMBO Journal	2002